Likarda leads in innovative approaches to cell therapy products by developing injectable, low-cost answers to treat diabetes in companion animals. Our product, currently in the pre-clinical stage, incorporates insulin-producing cells in a single administered injection by the client’s veterinarian as opposed to the twice daily insulin shots currently required to treat the disease. Cells are coated with a protective hydrogel using our patented CSS™ Microencapsulation system, resulting in transplants that are invisible to the immune system and don’t initiate inflammatory responses in the recipient. The process is versatile, enabling both durable and degradable versions, and can be applied to several cell therapies for pets and humans. To date, Likarda has been funded for over $10M through private investments and by conducting revenue-generating contract research for the pharmaceutical industry.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Insulin-Producing Cell Therapy for Diabetes
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):